Symphogen A/S - Product Pipeline Review

Global Markets Direct’s, ‘Symphogen A/S - Product Pipeline Review - 2016’, provides an overview of the Symphogen A/S’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Symphogen A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Symphogen A/S

The report provides overview of Symphogen A/S including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Symphogen A/S’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Symphogen A/S’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Symphogen A/S’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Symphogen A/S

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Symphogen A/S’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Symphogen A/S ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Symphogen A/S Snapshot 6

Symphogen A/S Overview 6

Key Facts 6

Symphogen A/S - Research and Development Overview 7

Key Therapeutic Areas 7

Symphogen A/S - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Pipeline Products - Combination Treatment Modalities 11

Symphogen A/S - Pipeline Products Glance 12

Symphogen A/S - Clinical Stage Pipeline Products 12

Phase II Products/Combination Treatment Modalities 12

Phase I Products/Combination Treatment Modalities 13

Symphogen A/S - Early Stage Pipeline Products 14

Preclinical Products/Combination Treatment Modalities 14

Discovery Products/Combination Treatment Modalities 15

Symphogen A/S - Drug Profiles 16

futuximab + modotuximab - Drug Profile 16

Product Description 16

Mechanism Of Action 16

R&D Progress 16

Monoclonal Antibodies 1 for Oncology - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

Monoclonal Antibodies for Oncology - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

Monoclonal Antibody to Antagonize PD1 for Oncology - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

Monoclonal Antibody to Inhibit LAG-3 for Oncology - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

Monoclonal Antibody to Inhibit TIM-3 for Oncology - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Sym-013 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

SYM-015 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Symphogen A/S - Pipeline Analysis 28

Symphogen A/S - Pipeline Products by Target 28

Symphogen A/S - Pipeline Products by Route of Administration 29

Symphogen A/S - Pipeline Products by Molecule Type 30

Symphogen A/S - Pipeline Products by Mechanism of Action 31

Symphogen A/S - Dormant Projects 32

Symphogen A/S - Discontinued Pipeline Products 33

Discontinued Pipeline Product Profiles 33

rozrolimupab 33

Symphogen A/S - Company Statement 34

Symphogen A/S - Locations And Subsidiaries 36

Head Office 36

Other Locations & Subsidiaries 36

Appendix 37

Methodology 37

Coverage 37

Secondary Research 37

Primary Research 37

Expert Panel Validation 37

Contact Us 37

Disclaimer 38

List of Tables

List of Tables

Symphogen A/S, Key Facts 6

Symphogen A/S - Pipeline by Indication, 2016 8

Symphogen A/S - Pipeline by Stage of Development, 2016 ...

List of Tables

Symphogen A/S, Key Facts 6

Symphogen A/S - Pipeline by Indication, 2016 8

Symphogen A/S - Pipeline by Stage of Development, 2016 9

Symphogen A/S - Monotherapy Products in Pipeline, 2016 10

Symphogen A/S - Combination Treatment Modalities in Pipeline, 2016 11

Symphogen A/S - Phase II, 2016 12

Symphogen A/S - Phase I, 2016 13

Symphogen A/S - Preclinical, 2016 14

Symphogen A/S - Discovery, 2016 15

Symphogen A/S - Pipeline by Target, 2016 28

Symphogen A/S - Pipeline by Route of Administration, 2016 29

Symphogen A/S - Pipeline by Molecule Type, 2016 30

Symphogen A/S - Pipeline Products by Mechanism of Action, 2016 31

Symphogen A/S - Dormant Developmental Projects,2016 32

Symphogen A/S - Discontinued Pipeline Products, 2016 33

Symphogen A/S, Subsidiaries 36

List of Figures

List of Figures

Symphogen A/S - Pipeline by Top 10 Indication, 2016 8

Symphogen A/S - Pipeline by Stage of Development, 2016 9

Symphogen A/S ...

List of Figures

Symphogen A/S - Pipeline by Top 10 Indication, 2016 8

Symphogen A/S - Pipeline by Stage of Development, 2016 9

Symphogen A/S - Monotherapy Products in Pipeline, 2016 10

Symphogen A/S - Combination Treatment Modalities in Pipeline, 2016 11

Symphogen A/S - Pipeline by Target, 2016 28

Symphogen A/S - Pipeline by Route of Administration, 2016 29

Symphogen A/S - Pipeline by Molecule Type, 2016 30

Symphogen A/S - Pipeline Products by Mechanism of Action, 2016 31

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports